Daniel Flynn
Pediatric Endocrinology · Boise, IDNPI 1447449574
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 63.3% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $34,883 and has fallen 87.3% since, to $4,418 in 2025.
Across 191 payments — averaging $561.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$68K
- Novo Nordisk$7K
- Medtronic$7K
- Ascendis Pharma Endocrinology Inc$6K
- Pfizer$5K
- Amgen$5K
- plus $9K from 17 others
Across 359 payments — averaging $1469.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$156K
- Novo Nordisk AS$76K
- Biomarin Pharmaceutical Inc.$75K
- OPKO Pharmaceuticals, LLC$69K
- Ascendis Pharma Endocrinology Inc$68K
- Sanofi US Services Inc.$62K
- plus $22K from 2 others
What the payments were for
- Consulting fees$22,07521%
- Speaking & faculty fees$62,91859%
- Travel & lodging$17,73117%
- Food & beverage$4,5614%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 81 | $67,881 |
| Novo Nordisk | 12 | $7,241 |
| Medtronic(2 entities) | 26 | $7,066 |
| Ascendis Pharma Endocrinology Inc | 9 | $6,460 |
| Pfizer | 8 | $5,349 |
| Amgen | 9 | $4,695 |
| Sanofi-aventis U.S. LLC | 5 | $4,361 |
| Eli Lilly | 5 | $1,416 |
| Endo Pharmaceuticals Inc. | 1 | $1,265 |
| Tolmar, Inc. | 2 | $674 |
| Ultragenyx Pharmaceutical Inc. | 5 | $296 |
| Tandem Diabetes Care, Inc. | 6 | $178 |
| Insulet Corporation | 8 | $162 |
| Rhythm Pharmaceuticals, Inc. | 4 | $93 |
| Dexcom, Inc. | 2 | $41 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| AstraZeneca | 1 | $17 |
| AbbVie | 1 | $15 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$21,637
- FreeStyle Libre$18,809
- FreeStyle Libre Pro$14,680
- FreeStyle Libre 2$12,257
- Norditropin$7,127
- SKYTROFA$6,338
- TEPEZZA$4,566
- NGENLA$3,710
- HUMALOG$1,416
- SUPPRELIN$1,265
- Minimed 670G System$923
- FENSOLVI$650
- CRYSVITA$237
- InPen$160
- TZIELD$157
How this compares
Too few pediatric endocrinology providers in Idahoto place this figure against a meaningful peer group, so we don't.
Other pediatric endocrinology in Boise
- Cydney FentonBoise$24K
- Joshua SmithIdaho Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.